Meiragtx

Meiragtx company information, Employees & Contact Information

Explore related pages

Related company profiles:

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

Company Details

Employees
395
Founded
-
Address
92 Brittania Walk, London/new York,n17nq,united Kingdom
Email
in****@****gtx.com
Industry
Biotechnology
HQ
London/New York
Looking for a particular Meiragtx employee's phone or email?

Meiragtx Questions

News

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy 2025 Annual Congress - Investing News Network

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy 2025 Annual Congress Investing News Network

MeiraGTx Holdings Receives RMAT Designation from FDA for AAV-GAD Gene Therapy in Parkinson's Disease - Quiver Quantitative

MeiraGTx Holdings Receives RMAT Designation from FDA for AAV-GAD Gene Therapy in Parkinson's Disease Quiver Quantitative

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital Seeking Alpha

MeiraGTx Announces Positive Results from First-in-Human Study of Gene Therapy for AIPL1-Related Retinal Dystrophy in Young Children - Nasdaq

MeiraGTx Announces Positive Results from First-in-Human Study of Gene Therapy for AIPL1-Related Retinal Dystrophy in Young Children Nasdaq

MeiraGTx Lands Massive $430M AI Deal While Hitting 100% Success in Gene Therapy Trial - Stock Titan

MeiraGTx Lands Massive $430M AI Deal While Hitting 100% Success in Gene Therapy Trial Stock Titan

AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire

AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight GlobeNewswire

MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval - Fierce Biotech

MeiraGTx gene therapy allows 11 blind children to see as biotech eyes accelerated approval Fierce Biotech

MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup - BioPharma Dive

MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup BioPharma Dive

Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial - MedCity News

Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial MedCity News

The Next Frontier in Parkinson Disease Care: Exploring Gene and Cell Therapies - NeurologyLive

The Next Frontier in Parkinson Disease Care: Exploring Gene and Cell Therapies NeurologyLive

MeiraGTx and Hologen Limited Announce $200 Million Collaboration and Formation of Hologen Neuro AI Ltd Joint Venture for Parkinson's Disease Development - Nasdaq

MeiraGTx and Hologen Limited Announce $200 Million Collaboration and Formation of Hologen Neuro AI Ltd Joint Venture for Parkinson's Disease Development Nasdaq

MeiraGTx Holdings: Gaining Regulatory Focus (NASDAQ:MGTX) - Seeking Alpha

MeiraGTx Holdings: Gaining Regulatory Focus (NASDAQ:MGTX) Seeking Alpha

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond - Fierce Biotech

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond Fierce Biotech

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week - Yahoo Finance

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week Yahoo Finance

Switching Gene Therapy On and Off with a Pill - Genetic Engineering and Biotechnology News

Switching Gene Therapy On and Off with a Pill Genetic Engineering and Biotechnology News

MeiraGTx seeks UK approval after gene therapy restores sight in children born blind - Pharmaceutical Technology

MeiraGTx seeks UK approval after gene therapy restores sight in children born blind Pharmaceutical Technology

GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings - NeurologyLive

GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings NeurologyLive

MeiraGTx Holdings Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

MeiraGTx Holdings Second Quarter 2025 Earnings: Misses Expectations Yahoo Finance

MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future - Yahoo Finance

MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future Yahoo Finance

MeiraGTx and Hologen launch AI-backed gene therapy venture - Pharmaceutical Technology

MeiraGTx and Hologen launch AI-backed gene therapy venture Pharmaceutical Technology

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates Yahoo Finance

MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment - Yahoo Finance

MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment Yahoo Finance

MeiraGTx shares jump on $200M deal with Hologen AI for Parkinson's therapy - FirstWord Pharma

MeiraGTx shares jump on $200M deal with Hologen AI for Parkinson's therapy FirstWord Pharma

MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study - Clinical Trials Arena

MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study Clinical Trials Arena

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data - BioPharma Dive

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data BioPharma Dive

MeiraGTx opens first commercial-scale gene therapy plant in Ireland - BioProcess International

MeiraGTx opens first commercial-scale gene therapy plant in Ireland BioProcess International

Sanofi invests in MeiraGTx and its gene-regulating technology - BioPharma Dive

Sanofi invests in MeiraGTx and its gene-regulating technology BioPharma Dive

MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech

MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial Fierce Biotech

On Heels of Positive Parkinson’s Gene Therapy Data, MeiraGTx Looks Ahead to Pivotal Test - MedCity News

On Heels of Positive Parkinson’s Gene Therapy Data, MeiraGTx Looks Ahead to Pivotal Test MedCity News

J&J bets bigger on MeiraGTx’s eye gene therapy - BioPharma Dive

J&J bets bigger on MeiraGTx’s eye gene therapy BioPharma Dive

There's Reason For Concern Over MeiraGTx Holdings plc's (NASDAQ:MGTX) Price - simplywall.st

There's Reason For Concern Over MeiraGTx Holdings plc's (NASDAQ:MGTX) Price simplywall.st

Dynamic range: the key to MeiraGTx’s quest to control genes with pills - BioCentury

Dynamic range: the key to MeiraGTx’s quest to control genes with pills BioCentury

MeiraGTx sells XLRP gene therapy to Janssen - European Pharmaceutical Review

MeiraGTx sells XLRP gene therapy to Janssen European Pharmaceutical Review

MeiraGTx earnings missed, revenue fell short of estimates - Investing.com

MeiraGTx earnings missed, revenue fell short of estimates Investing.com

MeiraGTx Holdings plc's (NASDAQ:MGTX) Shift From Loss To Profit - simplywall.st

MeiraGTx Holdings plc's (NASDAQ:MGTX) Shift From Loss To Profit simplywall.st

J&J takes full control of retinal disease gene therapy from MeiraGTx - FirstWord Pharma

J&J takes full control of retinal disease gene therapy from MeiraGTx FirstWord Pharma

MeiraGTx wins RPD designation for Leber candidate - The Pharma Letter

MeiraGTx wins RPD designation for Leber candidate The Pharma Letter

Sanofi pays $30M for first look at MeiraGTx's data and a shot to brew up deals - Fierce Biotech

Sanofi pays $30M for first look at MeiraGTx's data and a shot to brew up deals Fierce Biotech

MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M - Fierce Biotech

MeiraGTx gifts remaining gene therapy rights to J&J for up to $415M Fierce Biotech

MeiraGTx wins 3 Rare Pediatric designations and updates on AAV-AIPL1 - The Pharma Letter

MeiraGTx wins 3 Rare Pediatric designations and updates on AAV-AIPL1 The Pharma Letter

More could be to come for MeiraGTx after $30 million Sanofi investment - The Pharma Letter

More could be to come for MeiraGTx after $30 million Sanofi investment The Pharma Letter

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results - simplywall.st

Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results simplywall.st

MeiraGTx gene therapy for ALS rescues deficits in rodents with sporadic and familial forms - Fierce Biotech

MeiraGTx gene therapy for ALS rescues deficits in rodents with sporadic and familial forms Fierce Biotech

Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Mary Ann Liebert, Inc.

Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma Mary Ann Liebert, Inc.

MeiraGTx - IDA Ireland

MeiraGTx IDA Ireland

MeiraGTx advances Parkinsons gene therapy with RMAT approval - Traders Union

MeiraGTx advances Parkinsons gene therapy with RMAT approval Traders Union

Gene therapy startup MeiraGTx files for $86M IPO - Fierce Biotech

Gene therapy startup MeiraGTx files for $86M IPO Fierce Biotech

MGTX Stock Price and Chart — NASDAQ:MGTX - TradingView

MGTX Stock Price and Chart — NASDAQ:MGTX TradingView

Major expansion of Shannon facility announced by MeiraGTx - Engineers Ireland

Major expansion of Shannon facility announced by MeiraGTx Engineers Ireland

Top Meiragtx Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant